Company profile: DYSIS Medical
1.1 - Company Overview
Company description
- Provider of medical imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions, including the DYSIS Colposcope for imaging the cervix and lower genital tract with adjunctive acetowhitening display; DYSISmap to quantify acetowhitening and overlay a color-coded map to assist biopsy targeting; and DYSIS SMARTtrack for enhanced documentation with high-resolution images, video, and instant exam playback.
Products and services
- DYSISmap: Proprietary technology quantifies acetowhitening changes and overlays an intuitive color-coded map onto the live cervical image to assist in precisely targeting biopsy sites
- DYSIS Colposcope: Digital colposcope engineered to image the cervix and lower genital tract under illumination and magnification, featuring an adjunctive tool for displaying areas of aceto-whitening during examination
- DYSIS SMARTtrack: High-resolution documentation feature that records images and video with instant exam playback, enabling healthcare professionals to review exams and effectively direct the patient journey
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DYSIS Medical
Boundless Bio
HQ: United States
Website
- Description: Provider of precision oncology therapeutics and diagnostics targeting extrachromosomal DNA (ecDNA) in aggressive cancers, including BBI-355 (oral CHK1 inhibitor for ecDNA-enabled oncogene amplified cells), BBI-825 (oral RNR inhibitor disrupting ecDNA assembly and repair), the Spyglass platform to identify and validate druggable targets in ecDNA-cancer cells, and ECHO to detect ecDNA from routine clinical next-generation sequencing data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boundless Bio company profile →
Novian Health
HQ: United States
Website
- Description: Provider of proprietary interstitial laser therapy solutions for the focal destruction of breast tumors, including Novilase Breast Therapy, the Interstitial Laser System for breast-conserving procedures, and evidence-generation programs such as the ABLATE Registry and BR-003 clinical trial to support reimbursement and U.S. marketing clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novian Health company profile →
Amcure
HQ: Germany
Website
- Description: Provider of peptide-based compounds in clinical development for the treatment of highly metastatic forms of squamous cancer; a privately held spin-off from the Karlsruhe Institute of Technology established in 2012 and supported by a grant from the German Federal Ministry of Education and Research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amcure company profile →
Deciphera Pharmaceuticals
HQ: United States
Website
- Description: Provider of kinase inhibitor–based cancer medicines leveraging a proprietary switch-control platform. Commercializes Ripretinib (QINLOCK) for advanced gastrointestinal stromal tumor after treatment with three or more kinase inhibitors, and develops a pipeline including Vimseltinib (CSF1R) for TGCT, DCC-3116 (ULK1/2) for cancers with RAS/RAF mutations, DCC-3084 (pan-RAF), and DCC-3009 (next‑gen KIT).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deciphera Pharmaceuticals company profile →
Galvanize Therapeutics
HQ: United States
Website
- Description: Provider of a biomedical platform delivering therapeutic products and services, including Aliya™ PEF System, a pulsed electric field technology for soft tissue ablation in various medical applications such as oncology, and RheOx®, a device targeting chronic bronchitis symptoms by reducing mucus-producing airway cells through pulsed electric fields.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galvanize Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DYSIS Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DYSIS Medical
2.2 - Growth funds investing in similar companies to DYSIS Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DYSIS Medical
4.2 - Public trading comparable groups for DYSIS Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →